APA aipamena

Raedler, L. A. (2016). Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma. Am Health Drug Benefits.

Chicago Style aipamena

Raedler, Lisa A. "Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients With Relapsed Multiple Myeloma." Am Health Drug Benefits 2016.

MLA aipamena

Raedler, Lisa A. "Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients With Relapsed Multiple Myeloma." Am Health Drug Benefits 2016.